Table 2.

Independent Association Between Incomplete ART Adherence With CVD Events and Non-CVD-Related Mortality in Virally Suppressed Study Participants on ART

Characteristic	CVD-Related Eventsa Univariate/Multivariate	P Value	Non-CVD-Related Mortalityb Univariate/Multivariate	P Value
Incomplete ART adherencec
Missed ≥1 dose of ART in the last 4 wk
Model 1a: only considering CVD-related events	205/163
Univariate, n = 6971	1.11 (0.76–1.61)	0.59
Multivariate, n = 4750	1.35 (0.90–2.03)	0.15
Model 2a: Competing risk models with non-CVD-related death as a competing event with missing data imputed	205/205		186/186
Univariate, n = 6971	1.11 (0.76–1.61)	0.59	1.46 (1.02–2.09)	.04
Multivariate, n = 6971	1.23 (0.85–1.79)	0.28	1.44 (1.00–2.07)	.05
Incomplete ART adherencec
Missed ≥2 doses of ART in the last 4 wk
Model 1b: only considering CVD-related events	205/163
Univariate, n = 6971	1.08 (0.59–1.99)	0.80
Multivariate, n = 4750	1.32 (0.67–2.61)	0.42
Model 2b: Competing risk models with non-CVD-related death as a competing event with missing data imputed	205/205		186/186
Univariate, n = 6971	1.08 (0.59–1.99)	0.78	2.21 (1.38–3.56)	.001
Multivariate, n = 6971	1.25 (0.68–2.31)	0.48	2.21 (1.37–3.57)	.001

Abbreviations: ART, antiretroviral therapy; BMI, body mass index; CVD, cardiovascular disease; HR, hazard ratio.

^aCVD events include myocardial infarction, revascularization, cerebral hemorrhage, stroke, and/or death due to cardiovascular event.

^bAll reported deaths except those determined to be due to CVD.

^cResults give the HR and 95% CI; competing risk models give the cause-specific HR; adjusted models include gender, Caucasian ethnicity, injecting drug use, BMI, family history of CVD, Framingham risk score category, CD4⁺ T-cell count at ART initiation, HIV-1 RNA at ART initiation, first ART regimen class, and HIV-1 viral blips (single HIV-1 RNA >400 copies/mL followed by HIV-1 RNA <50 copies/mL).